AZD9291 in Advanced NSCLC

Susan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.

Clinical Pearls

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, provides an overview of the ongoing phase I/II AURA study, which aims to evaluate AZD9291 for patients previously treated with an EGFR TKI with advanced non-small cell lung cancer (NSCLC) with the T790M mutation.

  • The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291.
  • Responses are durable – median PFS is 9.6 months. Today, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.
  • AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.